D. Western Therapeutics Institute, Inc. (TYO:4576)
106.00
+2.00 (1.92%)
Apr 25, 2025, 3:30 PM JST
TYO:4576 Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 1,126 | 1,867 | 2,334 | 1,933 | 2,308 | Upgrade
|
Cash & Short-Term Investments | 1,126 | 1,867 | 2,334 | 1,933 | 2,308 | Upgrade
|
Cash Growth | -39.69% | -20.01% | 20.75% | -16.25% | 49.87% | Upgrade
|
Accounts Receivable | 125 | 117 | 170 | 101 | 91 | Upgrade
|
Receivables | 125 | 117 | 170 | 101 | 91 | Upgrade
|
Inventory | 101 | 87 | 79 | 88 | 58 | Upgrade
|
Other Current Assets | 123 | 66 | 76 | 40 | 46 | Upgrade
|
Total Current Assets | 1,475 | 2,137 | 2,659 | 2,162 | 2,503 | Upgrade
|
Property, Plant & Equipment | 11 | 10 | 10 | 4 | 5 | Upgrade
|
Long-Term Investments | 138 | 138 | 162 | 129 | 20 | Upgrade
|
Other Intangible Assets | 44 | 86 | 124 | 166 | 208 | Upgrade
|
Other Long-Term Assets | 1 | 2 | 1 | 1 | 1 | Upgrade
|
Total Assets | 1,669 | 2,373 | 2,956 | 2,462 | 2,737 | Upgrade
|
Current Portion of Long-Term Debt | 19 | 9 | 120 | 129 | 120 | Upgrade
|
Current Income Taxes Payable | 99 | 173 | 75 | 51 | 56 | Upgrade
|
Other Current Liabilities | 14 | 12 | 16 | 13 | 33 | Upgrade
|
Total Current Liabilities | 132 | 194 | 211 | 193 | 209 | Upgrade
|
Long-Term Debt | 778 | 875 | 847 | 210 | 340 | Upgrade
|
Other Long-Term Liabilities | 26 | 25 | 27 | 25 | 25 | Upgrade
|
Total Liabilities | 936 | 1,094 | 1,085 | 428 | 574 | Upgrade
|
Common Stock | 1,203 | 831 | 714 | 573 | 556 | Upgrade
|
Additional Paid-In Capital | 3,261 | 2,889 | 2,772 | 2,631 | 2,655 | Upgrade
|
Retained Earnings | -3,732 | -2,442 | -1,629 | -1,200 | -1,051 | Upgrade
|
Comprehensive Income & Other | 1 | 1 | -1 | 2 | 3 | Upgrade
|
Total Common Equity | 733 | 1,279 | 1,856 | 2,006 | 2,163 | Upgrade
|
Minority Interest | - | - | 15 | 28 | - | Upgrade
|
Shareholders' Equity | 733 | 1,279 | 1,871 | 2,034 | 2,163 | Upgrade
|
Total Liabilities & Equity | 1,669 | 2,373 | 2,956 | 2,462 | 2,737 | Upgrade
|
Total Debt | 797 | 884 | 967 | 339 | 460 | Upgrade
|
Net Cash (Debt) | 329 | 983 | 1,367 | 1,594 | 1,848 | Upgrade
|
Net Cash Growth | -66.53% | -28.09% | -14.24% | -13.74% | 74.34% | Upgrade
|
Net Cash Per Share | 9.37 | 30.93 | 46.12 | 54.34 | 68.01 | Upgrade
|
Filing Date Shares Outstanding | 45.28 | 32.13 | 31.32 | 29.36 | 29.31 | Upgrade
|
Total Common Shares Outstanding | 41.63 | 32.13 | 30.87 | 29.36 | 29.25 | Upgrade
|
Working Capital | 1,343 | 1,943 | 2,448 | 1,969 | 2,294 | Upgrade
|
Book Value Per Share | 17.61 | 39.81 | 60.12 | 68.33 | 73.95 | Upgrade
|
Tangible Book Value | 689 | 1,193 | 1,732 | 1,840 | 1,955 | Upgrade
|
Tangible Book Value Per Share | 16.55 | 37.13 | 56.10 | 62.67 | 66.84 | Upgrade
|
Updated Feb 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.